Beckman Coulter, Inc. manufactures and distributes biomedical testing instrument systems and general biomedical research products. It develops and markets products that simplify, automate and innovate complex biomedical testing. The firm’s systems operate in both diagnostics and life sciences laboratories on seven continents. Its products improve the productivity of medical professionals and scientists, supplying critical information for improving patient health and delivering trusted solutions for research and discovery. The company was founded in 1935 by Arnold O. Beckman and is headquartered in Brea, CA.

Abbott Laboratories engages in the discovery, development, manufacture, and sale of a broad and diversified line of health care products. It operates through the following business segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment refers to the international sales of a line of branded generic pharmaceutical products. The Diagnostic Products segment markets diagnostic systems and tests for blood banks, hospitals, commercial laboratories, and alternate-care testing sites. The Nutritional Products segment caters to the worldwide sales of adult and pediatric nutritional products. The Medical Devices segment includes electrophysiology, heart failure, vascular and structural heart devices for the treatment of cardiovascular diseases, and diabetes care products for people with diabetes, as well as neuromodulation devices for the management of chronic pain and movement disorders. The company was founded by Wallace Calvin Abbott in 1888 and is headquartered in Abbott Park, IL.

Bio-Rad Laboratories has played a leading role in the advancement of scientific discovery for over 50 years by providing a broad range of innovative tools and services to the life science research and clinical diagnostics markets. Founded in 1952, Bio-Rad has a global team of more than 6,500 employees and serves more than 85,000 research and industry customers worldwide through its global network of operations. Throughout its existence, Bio-Rad has built strong customer relationships that advance scientific research and development efforts and support the introduction of new technology used in the growing fields of genomics, proteomics, drug discovery, food safety, medical diagnostics, and more.

Siemens Healthcare Diagnostics, Inc. engages in the vitro diagnostics. It provides healthcare professionals in hospital, reference, and physician office laboratories and point-of-care settings with the vital information required to accurately diagnose, treat, and monitor patients. The company is headquartered in Tarrytown, NY.

Bayer Corp. manufactures and markets pharmaceutical, healthcare, nutrition and materials products. The firm offers consumer care, diagnostics, diabetes and animal health products. It also provides material science products, which include coating, adhesive and sealant raw materials polycarbonates polyurethanes and thermoplastic polyurethane elastomers. The company was founded in 1973 and is based in Whippany, NJ.

Becton, Dickinson & Co. engages in the development, manufacture, and sale of medical supplies, devices, laboratory equipment, and diagnostic products. It operates through the following segments: BD Medical, BD Life Sciences, and BD Interventional. The BD Medical segment produces medical technologies and devices that are used to help improve healthcare delivery. The BD Life Sciences segment provides products for the safe collection and transport of diagnostics specimens, and instruments and reagent systems to detect infectious diseases, healthcare-associated infections, and cancers. The BD Interventional segment offers vascular, urology, oncology, and surgical specialty products to hospitals, individual healthcare professionals, extended care facilities, alternate site facilities, and patients via its Homecare business. The company was founded by Maxwell W. Becton and Fairleigh S. Dickinson in 1897 and is headquartered in Franklin Lakes, NJ.

IDEXX Laboratories, Inc. engages in the development, manufacture, and distribution of products and services for the animal veterinary, livestock and poultry, dairy and water testing markets. It operates through the following segments: Companion Animal Group (CAG), Water, Livestock, Poultry and Dairy (LPD), and Other. The CAG segment provides diagnostic and information management-based products and services for the companion animal veterinary industry, including in-clinic diagnostic solutions, outside reference laboratory services, and veterinary software and services. The Water segment offers innovative testing solutions for easy, rapid, and accurate detection and quantification of various microbiological parameters in water. The LPD segment develops diagnostic tests, services, and related instrumentation that are used to manage the health status of livestock and poultry, to improve producer efficiency, and to ensure the quality and safety of milk and food. The Other segment is composed of products for the human point-of-care medical diagnostics market with its out-licensing arrangements. The company was founded by David Evans Shaw on December 19, 1983, and is headquartered in Westbrook, ME.

Makes systems for blood and cell analysis

Bayer HealthCare AG provides healthcare, agriculture, plastics and chemical products. It is an independent company comprising five divisions: Animal Health, Consumer Care, Diabetes Care, Diagnostics and Pharmaceuticals. The company covers the fields of animal health, genetically produced medicines, over the counter products, diagnostic products and prescription drugs. The company is headquartered in Leverkusen, Germany.

IRIS International, Inc. is a manufacturer of automated in vitro diagnostic systems (IVD), sample processing products and personalized diagnostics tests for use in hospitals and laboratories worldwide. The Company’s IVD products analyze the chemistry and morphology of cells and sediments in a variety of body fluids. It is also a provider of automated urine microscopy systems, with more than 3,600 iQ microscopy analyzers shipped to date in over 50 countries. It is focused on developing, manufacturing and commercializing in vitro diagnostics instruments and consumables for urinalysis, including its flagship iQ analyzers, a family of fully-automated, image-based bench-top analyzers for urine microscopy. Its commercialized products and product pipeline comprise three main categories: morphology, sample processing and personalized medicine.

Streck develops and delivers control and diagnostic products that help validate the reputation of laboratories, hospitals, and clinicians all over the world. Their services include biotechnology, clinical controls, hematology, immunology, flow cytometry, chemistry, urinalysis, and qc devices.

General Data Co., Inc. is a provider of labeling, identification, tracking, and printer service solutions. The firm’s products include barcode labels & tags, barcode scanners, healthcare barcode scanners, genkote coated products, genkote coated products, mobile computers, healthcare mobile computers, printers, healthcare printers, mobile workstations, thermal transfer ribbons, toner, ink & printer supplies, software, wristbands, histology equipment, histology supplies and reagents. It also offers barcode scanning & data collection, custom application development, custom label manufacturing, enterprise mobility services, labeling and identification, printer repair service, printer supplies replenishment, toll and custom coating and wireless network infrastructure services. The company was founded by Peter Wenzel in 1981 and is headquartered in Cincinnati, OH.

Boule Medical AB, part of Boule Diagnostics AB, is a Swedish company located in Stockholm. The firm develops and produces blood cell counter systems.

CAVΛDIS™ is a Dutch biomedical company active in the field of cardiovascular risk assessment. They develop prognostic tests to identify patients at risk of cardiovascular and disease. The company identified several novel biomarkers predictive for cardiovascular events. It is their goal is to develop clinically meaningful risk stratification tools that will help personalize treatment and achieve better patient outcomes.